Technology Potential
Projected Earnings from the BioClonetics’ passive immunotherapy have been calculated by an independent national consulting firm. This analysis examines the expected potential profits from 2 perspectives: (1) considering sales only to North America and Western Europe and (2) considering sales to the major Markets including North America, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America. The potential earnings and underlying assumptions for application of our passive immunotherapy to major Markets are set forth here:
Potential Profit from Technology
Assumptions for passive immunotherapy predictive Earnings – 7 Major Markets
Patient Population:
Major Markets – HIV population[1]
North America, Western and Central Europe - 2.2 million
Eastern Europe and Central Asia – 1.4 million
South and Southeast Asia (including India) – 5.2 million
Latin America – 1.8 million
Total – 10.6 million
Assumes 10.6 million potential patient populations with HIV/AIDS
· Assumes 1.5% annual increase in potential population growth over the forecast period
· $8,000 treatment total cost per patient (single series of treatments for one year only)
· Assumes penetration of from 1% in year one to maximum of 15%
· Assumes a reduction in the population group by the number treated
[1] https://www.avert.org/global-hiv-and-aids-statistics
A vaccine against HIV has a much broader application and will produce significantly larger earnings.
An HIV vaccine.